Vitamin D receptor expression in invasive breast tumors and breast cancer survival

Breast Cancer Research

Table 2 Vitamin D receptor expression in relation to breast cancer mortality

		Total (n)	Person-years	Dead from breast cancer	Breast cancer mortality/100 000	HR^a	HR^b	HR^c,#	HR^c,*
Nuclear VDR fraction	0–10% (neg)	125	1310	34	2595	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
Nuclear VDR fraction	11–100% (pos)	553	6414	77	1200	0.46 (0.31–0.69)	0.42 (0.28–0.63)	0.61 (0.35–1.05)	0.56 (0.34–0.91)
Nuclear VDR fraction	0–10%	125	1310	34	2595	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
	11–50%	437	5055	61	1206	0.47 (0.31–0.71)	0.41 (0.27–0.63)	0.57 (0.32–1.01)	0.54 (0.32–0.89)
	51–100%	116	1359	16	1177	0.46 (0.25–0.83)	0.44 (0.24–0.79)	0.74 (0.35–1.55)	0.66 (0.34–1.28)
Cytoplasmic VDR score	0–6 (neg)	57	609	17	2791	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
Cytoplasmic VDR score	7–12 (pos)	622	7137	94	1317	0.47 (0.28–0.79)	0.44 (0.26–0.74)	0.88 (0.39–1.97)	0.59 (0.30–1.16)
Cytoplasmic VDR score	0–6	57	609	17	2791	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
	7–9	152	1712	25	1460	0.52 (0.28–0.96)	0.50 (0.27–0.92)	1.01 (0.43–2.40)	0.58 (0.27–1.24)
	10–12	470	5425	69	1272	0.45 (0.27–0.77)	0.42 (0.25–0.72)	0.81 (0.36–1.86)	0.59 (0.30–1.18)

^aCrude analysis
^bAdjusted for age at and season of diagnosis
^cAdjusted for same factors as ^b but also for size of tumor, lymph node status, histological type, and molecular subtypes
^#Complete case analysis: analysis including only cases with complete information on all covariates
*Multiple imputation performed to include individuals with missing data on covariates in analysis

ISSN: 1465-542X